Johannes F. Scheid

Johannes F. Scheid

Auto-generated profile, based on publicly available information

Johannes F. Scheid

Broad Institute of MIT and Harvard 1 , Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JSJohannes F. Scheid
Johannes F. Scheid
BEBasak Eraslan
Basak Eraslan
AHAndrew Hudak
Andrew Hudak
EBEric M. Brown
Eric M. Brown
DSDallis Sergio
Dallis Sergio
RXRamnik J. Xavier
Ramnik J. Xavier
Plasma cells (PCs) constitute a significant fraction of colonic mucosal cells and contribute to inflammatory infiltrates in ulcerative colitis (UC). While gut PCs secrete bacteria-targeting IgA antibodies, their role in UC pathogenesis is unknown. We performed single-cell V(D)J- and RNA-seq on sorted B cells from the colon of healthy individuals and patients with UC. A large fraction of B cell clones is shared between different colon regions, but inflammation in UC broadly disrupts this landscape, causing transcriptomic changes characterized by an increase in the unfolded protein response (UPR) and antigen presentation genes, clonal expansion, and isotype skewing from IgA1 and IgA2 to IgG1. We also directly expressed and assessed the specificity of 152 mAbs from expanded PC clones. These mAbs show low polyreactivity and autoreactivity and instead target both shared bacterial antigens and specific bacterial strains. Altogether, our results characterize the microbiome-specific colon PC response and how its disruption might contribute to inflammation in UC.

1 March 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
VLValérie Lorin
Valérie Lorin
IFIgnacio Fernández
Ignacio Fernández
GMGuillemette Masse-Ranson
Guillemette Masse-Ranson
MBMélanie Bouvin-Pley
Mélanie Bouvin-Pley
LMLuis M Molinos-Albert
Luis M Molinos-Albert
HMHugo Mouquet
Hugo Mouquet
Decrypting the B cell ontogeny of HIV-1 broadly neutralizing antibodies (bNAbs) is paramount for vaccine design. Here, we characterized IgA and IgG bNAbs of three distinct B cell lineages in a viremic controller, two of which comprised only IgG+ or IgA+ blood memory B cells; the third combined both IgG and IgA clonal variants. 7-269 bNAb in the IgA-only lineage displayed the highest neutralizing capacity despite limited somatic mutation, and delayed viral rebound in humanized mice. bNAbs in all three lineages targeted the N332 glycan supersite. The 2.8-Å resolution cryo-EM structure of 7-269-BG505 SOSIP.664 complex showed a similar pose as 2G12, on an epitope mainly composed of sugar residues comprising the N332 and N295 glycans. Binding and cryo-EM structural analyses showed that antibodies from the two other lineages interact mostly with glycans N332 and N386. Hence, multiple B cell lineages of IgG and IgA bNAbs focused on a unique HIV-1 site of vulnerability can codevelop in HIV-1 viremic controllers.

2 November 2021 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
JSJohannes F. Scheid
Johannes F. Scheid
MRMatthew W. Rosenbaum
Matthew W. Rosenbaum
EPEric M. Przybyszewski
Eric M. Przybyszewski
KKKumar Krishnan
Kumar Krishnan
DFDavid G. Forcione
David G. Forcione
DPDaniel S. Pratt
Daniel S. Pratt